Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics and keeping the price target at $180.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Axsome Therapeutics’ promising growth trajectory. The company reported a strong top-line performance in the second quarter of 2025, with revenues exceeding expectations. Despite a wider-than-anticipated net loss, largely due to increased operating expenses, the revenue growth and strategic investments indicate potential for future profitability.
Axsome’s flagship product, AUVELITY, has shown significant sales growth and expanded payer coverage, suggesting robust market acceptance and potential for substantial revenue generation. Additionally, the successful launch and promising differentiation of SYMBRAVO further bolster the company’s growth prospects. These elements, combined with management’s optimistic sales projections for AUVELITY and strategic partnerships for SYMBRAVO, underpin Selvaraju’s confidence in Axsome’s future performance, justifying the Buy rating and a 12-month target of $180.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Urogen Pharma, and Cognition Therapeutics. According to TipRanks, Selvaraju has an average return of 18.8% and a 52.12% success rate on recommended stocks.
In another report released today, UBS also maintained a Buy rating on the stock with a $144.00 price target.